Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
CCXI's Cash-to-Debt is ranked higher than
82% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CCXI' s Cash-to-Debt Range Over the Past 10 Years
Min: 61.8  Med: 264.91 Max: No Debt
Current: No Debt
Equity-to-Asset 0.32
CCXI's Equity-to-Asset is ranked lower than
81% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CCXI: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
CCXI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.77 Max: 0.95
Current: 0.32
0.32
0.95
Interest Coverage No Debt
CCXI's Interest Coverage is ranked higher than
81% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CCXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CCXI' s Interest Coverage Range Over the Past 10 Years
Min: 206.51  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -0.59
Beneish M-Score: 7.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -341.18
CCXI's Operating Margin % is ranked lower than
64% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. CCXI: -341.18 )
Ranked among companies with meaningful Operating Margin % only.
CCXI' s Operating Margin % Range Over the Past 10 Years
Min: -731.32  Med: -179.14 Max: 31.55
Current: -341.18
-731.32
31.55
Net Margin % -334.84
CCXI's Net Margin % is ranked lower than
65% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. CCXI: -334.84 )
Ranked among companies with meaningful Net Margin % only.
CCXI' s Net Margin % Range Over the Past 10 Years
Min: -736.13  Med: -174.71 Max: 31.41
Current: -334.84
-736.13
31.41
ROE % -67.48
CCXI's ROE % is ranked lower than
66% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. CCXI: -67.48 )
Ranked among companies with meaningful ROE % only.
CCXI' s ROE % Range Over the Past 10 Years
Min: -67.48  Med: -33.61 Max: 20.21
Current: -67.48
-67.48
20.21
ROA % -34.61
CCXI's ROA % is ranked lower than
51% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CCXI: -34.61 )
Ranked among companies with meaningful ROA % only.
CCXI' s ROA % Range Over the Past 10 Years
Min: -48.48  Med: -31.15 Max: 15.1
Current: -34.61
-48.48
15.1
ROC (Joel Greenblatt) % -4611.55
CCXI's ROC (Joel Greenblatt) % is ranked lower than
79% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. CCXI: -4611.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CCXI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4611.55  Med: -2689.25 Max: 66.57
Current: -4611.55
-4611.55
66.57
3-Year Revenue Growth Rate 20.20
CCXI's 3-Year Revenue Growth Rate is ranked higher than
71% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. CCXI: 20.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CCXI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 20.2
Current: 20.2
0
20.2
3-Year EBITDA Growth Rate -1.90
CCXI's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. CCXI: -1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CCXI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -0.6 Max: 129.2
Current: -1.9
0
129.2
3-Year EPS without NRI Growth Rate -3.30
CCXI's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CCXI: -3.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CCXI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.3 Max: 105.2
Current: -3.3
0
105.2
GuruFocus has detected 2 Warning Signs with ChemoCentryx Inc $CCXI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CCXI Guru Trades in Q1 2016

Jim Simons 169,054 sh (+281.61%)
Steven Cohen Sold Out
Chuck Royce 32,900 sh (-1.20%)
» More
Q2 2016

CCXI Guru Trades in Q2 2016

Chuck Royce Sold Out
Jim Simons 69,681 sh (-58.78%)
» More
Q3 2016

CCXI Guru Trades in Q3 2016

Jim Simons 197,981 sh (+184.12%)
» More
Q4 2016

CCXI Guru Trades in Q4 2016

Jim Simons 470,581 sh (+137.69%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:NAS:ARNA, NAS:AKBA, AMEX:BTX, NAS:BSTC, NAS:BOLD, NAS:OMED, NAS:IDRA, NAS:NVAX, NAS:FOMX, NAS:GERN, OTCPK:PTCHF, NAS:MRUS, OTCPK:DGJI, NAS:OBSV, NAS:AVDL, NAS:AGEN, NAS:PDLI, NAS:SVA, NAS:PRTK, OTCPK:CNBX » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Chemocentryx is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are: antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 11.33
CCXI's Price-to-Owner-Earnings is ranked higher than
77% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. CCXI: 11.33 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CCXI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.84  Med: 10.03 Max: 14.31
Current: 11.33
6.84
14.31
PB Ratio 6.84
CCXI's PB Ratio is ranked lower than
73% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CCXI: 6.84 )
Ranked among companies with meaningful PB Ratio only.
CCXI' s PB Ratio Range Over the Past 10 Years
Min: 0.74  Med: 2.93 Max: 8.67
Current: 6.84
0.74
8.67
PS Ratio 28.31
CCXI's PS Ratio is ranked lower than
65% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. CCXI: 28.31 )
Ranked among companies with meaningful PS Ratio only.
CCXI' s PS Ratio Range Over the Past 10 Years
Min: 11.76  Med: 73.9 Max: 519.44
Current: 28.31
11.76
519.44
Price-to-Free-Cash-Flow 8.31
CCXI's Price-to-Free-Cash-Flow is ranked higher than
85% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. CCXI: 8.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CCXI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.07  Med: 7.44 Max: 10.5
Current: 8.31
5.07
10.5
Price-to-Operating-Cash-Flow 8.31
CCXI's Price-to-Operating-Cash-Flow is ranked higher than
85% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. CCXI: 8.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CCXI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.06  Med: 7.42 Max: 10.44
Current: 8.31
5.06
10.44
Current Ratio 3.88
CCXI's Current Ratio is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CCXI: 3.88 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 3.88  Med: 9.17 Max: 19.54
Current: 3.88
3.88
19.54
Quick Ratio 3.88
CCXI's Quick Ratio is ranked higher than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CCXI: 3.88 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 3.88  Med: 9.17 Max: 19.54
Current: 3.88
3.88
19.54
Days Sales Outstanding 923.74
CCXI's Days Sales Outstanding is ranked lower than
99% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. CCXI: 923.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.84  Med: 104.12 Max: 923.74
Current: 923.74
5.84
923.74

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
CCXI's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CCXI: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15  Med: -6.7 Max: 0
Current: -3.9
-15
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 28.56
CCXI's Price-to-Net-Cash is ranked lower than
86% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. CCXI: 28.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CCXI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.97  Med: 4.55 Max: 30.96
Current: 28.56
1.97
30.96
Price-to-Net-Current-Asset-Value 8.02
CCXI's Price-to-Net-Current-Asset-Value is ranked lower than
64% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. CCXI: 8.02 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CCXI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 4.49 Max: 8.7
Current: 8.02
1.95
8.7
Price-to-Tangible-Book 6.87
CCXI's Price-to-Tangible-Book is ranked lower than
68% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CCXI: 6.87 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CCXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.71  Med: 3.6 Max: 7.44
Current: 6.87
1.71
7.44
Price-to-Median-PS-Value 0.38
CCXI's Price-to-Median-PS-Value is ranked higher than
86% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CCXI: 0.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CCXI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.51 Max: 0.96
Current: 0.38
0.38
0.96
Earnings Yield (Greenblatt) % -18.01
CCXI's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. CCXI: -18.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CCXI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.46  Med: 0 Max: 1271.65
Current: -18.01
-18.46
1271.65

More Statistics

Revenue (TTM) (Mil) $11.94
EPS (TTM) $ -0.87
Beta2.05
Short Percentage of Float9.74%
52-Week Range $1.92 - 9.10
Shares Outstanding (Mil)48.15
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Immune Design Insider Buys Shares Oct 03 2016 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : March 24, 2017 Mar 24 2017
ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating... Mar 22 2017
CHEMOCENTRYX, INC. Financials Mar 18 2017
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Mar 17 2017
Edited Transcript of CCXI earnings conference call or presentation 14-Mar-17 9:00pm GMT Mar 15 2017
ChemoCentryx reports 4Q loss Mar 14 2017
ChemoCentryx reports 4Q loss Mar 14 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 14 2017
ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results Mar 14 2017
Q4 2016 ChemoCentryx Inc Earnings Release - After Market Close Mar 14 2017
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix Mar 10 2017
Sio Capital Remains Bullish On These Stocks Despite Weak Performance Mar 03 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 02 2017
ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14,... Mar 01 2017
ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference Feb 28 2017
Coverage initiated on ChemoCentryx by JMP Securities Feb 21 2017
CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 14 2017
Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases Feb 14 2017
ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor... Jan 20 2017
ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the... Jan 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)